| abstract |
(57) [Summary] [Constitution] The present invention relates to tocaracetin, which is a Tokara hab-derived polypeptide specified by molecular weight, components, size, and N-terminal amino acid partial sequence. [Effect] By inhibiting the binding between vWF and platelet membrane GPIb, It has a property of inhibiting WF-dependent platelet aggregation and not causing platelet aggregation by itself, and as an excellent antithrombotic agent that inhibits only platelet aggregation due to high shear stress, it can prevent a wide range of thromboembolism or the like. Useful as a therapeutic drug. |